Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Andre Elias Nel · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $512,817 — The use of nano-enabled chemotherapy to trigger an immune response to pancreatic ductal adenocarcinoma (PDAC) introduces a novel approach for overcoming robust barriers to immunotherapy, including poor immunogenicity, low neoantigen burden, stromal interference (“T-cell exclusion”), overexpression o…
JOHN M MARIS · CHILDREN'S HOSP OF PHILADELPHIA · 2023 · $839,128 — PROJECT SUMMARY This Multiple Principal Investigator (MPI) Project proposal for the Pediatric Immunotherapy Network is focused on high-risk neuroblastoma, a diverse and enigmatic malignancy arising from the developing sympathetic nervous system that remains lethal in 50% of patients despite intensiv…
GREGORY W FARIS · NUMENTUS TECHNOLOGIES INC. · 2023 · $298,794 — PROJECT SUMMARY There is growing recognition that extracellular vesicles (EVs)–micrometer- or nanometer-sized lipid particles containing protein and nucleic acid cargoes–are shed by all domains of life. The ubiquity of prokaryotic EVs suggests that the presence of bacterial EVs in biofluids could b…
Cynthia Arbeeny · MITOTHERAPEUTIX, LLC · 2023 · $1,008,980 — Abstract The goal of this SBIR fast-track application is to carry out a number of IND enabling studies on our siRNA drug candidate, which is designed to treat non-alcohol steatohepatitis (NASH). NASH is a form of non-alcohol fatty liver disease (NAFLD) and results from a pathological accumulation of…
Qingxin Mu · UNIVERSITY OF WASHINGTON · 2023 · $199,842 — Project Description Triple negative breast cancer (TNBC) is the most challenging subtype to treat among all breast cancer cases due to lack of cell surface receptors. Patients with metastatic TNBC have median overall survival of only 13.3 months with treatment. Newly approved immune checkpoint inhi…
Karen N. Allen · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $437,559 — Complex glycoconjugates play a pivotal role in bacterial survival, colonization and virulence and contribute to the interactions between symbiotic and pathogenic bacteria and their human hosts. An important mechanism for the assembly of these structures is initiated on the cytoplasmic face of cell m…
Shanthi K Srinivasan · VETERANS HEALTH ADMINISTRATION · 2023 — Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease in veterans and its prevalence continues to increase, with the growing obesity epidemic. Currently more than 25% of our veterans are obese and a larger number are overweight. In this proposal, we will examine the pl…
JINGFANG JU · NORTHPORT VA MEDICAL CENTER · 2023 — Project Summary/Abstract The goal of this application is to investigate the roles of miR-15a in colorectal cancer and to develop novel miR-15a mimic as potential therapeutics to treat advanced metastatic colorectal cancer in both male and female Veterans. Despite advancements in early detection and …
Shuibing Chen · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $729,080 — Abstract. Extracellular vesicles and particles (EVPs) are a group of heterogeneous nanoparticles that are secreted into the extracellular milieu by many types of cells. EVPs have emerged as important mediators in cell-to-cell communications within organs. Recent studies have suggested that EVPs migh…
William H. Peranteau · CHILDREN'S HOSP OF PHILADELPHIA · 2023 · $737,418 — PROJECT SUMMARY Metabolic liver diseases are the second most common indication for a pediatric liver transplant. Hereditary tyrosinemia type I (HT1) is a metabolic liver disease that results from FAH gene mutations causing a deficiency in fumarylacetoacetate hydrolase (FAH), the last enzyme in the t…
Ke Cheng · COLUMBIA UNIV NEW YORK MORNINGSIDE · 2023 · $675,040 — PROJECT SUMMARY Heart disease is the leading cause of death in the United States. About 875,000 Americans die from heart disease each year, of which 50-60% deaths are caused by coronary artery disease (CAD). CAD, the most common type of heart disease, can lead to heart attack and sudden death. Whil…
ZHENG-RONG LU · CASE WESTERN RESERVE UNIVERSITY · 2023 · $75,403 — The goal of this project is to develop smart dual-targeted lipid ECO/siRNA self-assembly nanoparticles to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat metastatic and drug-resistant triple negative breast cancer (TNBC). Metastasis and drug resistance are the main causes…
Arif Yurdagul · LOUISIANA STATE UNIV HSC SHREVEPORT · 2023 · $249,000 — Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the industrialized world. Most atherosclerotic plaques are clinically silent; however, a subset can lead to myocardial infarction, stroke, or sudden death. Atheromas that are linked to clinical events are characterized by …
BRETT M. MORRISON · JOHNS HOPKINS UNIVERSITY · 2023 · $450,313 — Summary Peripheral nerve injuries, whether the result of trauma, surgical complications, or neuropathies, afflict millions of people in the United States alone and are a major cause of disability and suffering throughout the world. The symptoms of peripheral nerve injury include numbness, tingling, …
Or Shemesh · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2023 · $238,500 — Abstract Glia are supportive cells in the human brain, comprising microglia, oligodendrocytes, astrocytes, and ependymal cells. Glia are deeply involved in diseases of the nervous system such as Alzheimer’s (AD), autism, pain, affective disorders, and cancers. Different glial cell types play differe…
Pranoti Mandrekar · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $561,807 — ABSTRACT Liver immune cell activation is central to alcohol associated liver disease (ALD) and is poorly understood. The protein homeostasis network/pathways are crucial in safeguarding the cellular proteome from cellular stress. Amongst these, proteostasis mediator HSP90 is widely studied and exte…
Ninh La-Beck · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · 2023 · $497,111 — ABSTRACT Drug delivery using liposomes increases tumor drug accumulation while sparing normal tissue. Several liposomal chemotherapies are approved to treat cancer. Unfortunately, lipid nanoparticles such as liposomes interact with the immune system and their impact on the tumor immunologic milieu i…
William R. Freeman · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $423,374 — ABSTRACT Diabetic retinopathy is a leading cause of blindness in the industrialized world and has a global prevalence of an estimated 95 million people (1). Proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) originate from persistently elevated glucose levels leading to microv…
Irina V Balyasnikova · UNIVERSITY OF COLORADO DENVER · 2023 · $563,302 — Project Abstract Glioblastoma (GBM) is the most devastating and aggressive brain tumor in adults, with patients surviving a median of only 14.6 months. Hidden behind the blood-brain and blood tumor-barrier (BBTB), the glioma cells migrating away from the tumor and invading surrounding brain tissue, …
David Scott Johnson · GIGAMUNE, INC. · 2023 · $295,294 — PROJECT SUMMARY Project Title: Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy Organization: GigaMune Inc. PI: David Johnson, Ph.D. Duchenne’s muscular dystrophy (DMD) is a severe, incurable, X-linked recessive disorder resulting in chronic muscle wasting caused by any of >7,…